Stockscreener 앱 받기
14.96
2.26%
0.33
시간 외 거래:
15.16
0.20
+1.34%
Summit Therapeutics Inc 주식(SMMT)의 최신 뉴스
Is Summit Therapeutics Inc. stock near bottom after decline2025 Major Catalysts & Free Fast Entry Momentum Trade Alerts - mfd.ru
Can Summit Therapeutics Inc. stock outperform in a bear marketWeekly Profit Summary & Weekly Setup with High ROI Potential - mfd.ru
Analysis Recap: How is STSSW managing supply chain issuesJuly 2025 Review & Daily Stock Momentum Reports - baoquankhu1.vn
Is Summit Therapeutics Inc. (SMMT) One of the Most Oversold NASDAQ Stocks to Invest In? - Bitget
FDA accepts Summit Therapeutics’ (SMMT) BLA for ivonescimab in NSCLC with November 14 PDUFA date following positive phase III data - MSN
Summit Therapeutics Insiders Placed Bullish Bets Worth US$275.0m - 富途牛牛
Summit Therapeutics (SMMT) Is Up 6.5% After FDA Accepts Ivonescimab BLA With 2026 PDUFA Date - simplywall.st
Is Summit Therapeutics Inc. stock a good pick for beginnersMarket Activity Report & Risk Controlled Daily Plans - baoquankhu1.vn
Summit Therapeutics Enters FDA Review As Ivonescimab Trials Broaden Potential - Sahm
First Week of February 20th Options Trading For Summit Therapeutics (SMMT) - Nasdaq
Summit Therapeutics PLC (NASDAQ:SMMT) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Is Summit Therapeutics (SMMT) Pricing Reflecting Its Recent Share Price Pullback Accurately - Yahoo Finance
Technical Reactions to SMMT Trends in Macro Strategies - Stock Traders Daily
Summit Therapeutics (NASDAQ:SMMT) Rating Lowered to Strong Sell at Zacks Research - MarketBeat
FDA Accepts Summit Therapeutics’ (SMMT) BLA For Ivonescimab In NSCLC With November 14 PDUFA Date Following Positive Phase III Data - Yahoo Finance
Summit Therapeutics stock hits 52-week low at 14.01 USD By Investing.com - Investing.com Canada
FDA Accepts Summit Therapeutics' (SMMT) BLA For Ivonescimab In NSCLC With November 14 PDUFA Date Following Positive Phase III Data - Finviz
Merger Talk: Is Summit Therapeutics Inc impacted by rising rates2025 Buyback Activity & Fast Moving Stock Trade Plans - baoquankhu1.vn
Summit Therapeutics (NASDAQ:SMMT) Reaches New 12-Month LowShould You Sell? - MarketBeat
Summit Incurs In-Line Q4 Loss, Inks Collaboration Deal With Pfizer - MSN
Summit Therapeutics (SMMT) Stock Analysis: A Potential 128% Upside In Biotech - DirectorsTalk Interviews
HC Wainwright Reaffirms Buy Rating for Summit Therapeutics (NASDAQ:SMMT) - MarketBeat
H.C. Wainwright reiterates Buy rating on Summit Therapeutics stock - Investing.com
Summit Therapeutics (SMMT) Analyst Ratings Reaffirmed at Buy | S - GuruFocus
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)January 30, 2026 - BioSpace
Encouraging guidance on clinical program makes Summit Therapeutics (SMMT) look attractive - MSN
2 Stocks That Could Soar This Year - The Globe and Mail
Summit spikes as lead asset undergoes FDA review - MSN
Yong Rong HK Asset Management Ltd Invests $2.07 Million in Summit Therapeutics PLC $SMMT - MarketBeat
FDA Accepts SMMT's Application Seeking Approval for NSCLC Drug - Finviz
Summit Therapeutics (SMMT) Analyst Rating Update: January 30, 20 - GuruFocus
Summit Therapeutics' (SMMT) Market Outperform Rating Reiterated at Citizens Jmp - MarketBeat
Summit Therapeutics: PDUFA Coming, But Is It Good Enough? (Rating Upgrade) (NASDAQ:SMMT) - Seeking Alpha
Summit Therapeutics stock gets FDA acceptance for ivonescimab BLA - Investing.com
Summit Therapeutics stock gets FDA acceptance for ivonescimab BLA By Investing.com - Investing.com Canada
US regulator accepts Summit filing for ivonescimab combo - The Pharma Letter
Summit Therapeutics (SMMT) Valuation Check After Recent Share Price Pullback And Conflicting Model Signals - Yahoo Finance
FDA Accepts Summit Therapeutics' BLA for Ivonescimab - intellectia.ai
FDA Accepts Summit's Lung Cancer Drug Application, Review Underway - Benzinga
Aug Gainers: Is Summit Therapeutics Inc impacted by rising rates2025 Risk Factors & Growth Focused Stock Reports - baoquankhu1.vn
Summit Therapeutics (SMMT) Advances with FDA Filing for Cancer T - GuruFocus
Summit Therapeutics Says US FDA Accepts BLA for Ivonescimab - marketscreener.com
Summit Therapeutics (SMMT) Gains After FDA Accepts Key Cancer Dr - GuruFocus
Summit Therapeutics’ Ivonescimab BLA Accepted by FDA - TipRanks
Summit Therapeutics stock rises after FDA accepts BLA for lung cancer drug By Investing.com - Investing.com South Africa
Summit spikes as lead asset gets FDA review (SMMT:NASDAQ) - Seeking Alpha
Summit Therapeutics stock rises after FDA accepts BLA for lung cancer drug - Investing.com Nigeria
Summit Therapeutics Inc FDA Accepts Ivonescimab BLA for NSCLC Treatment - TradingView
FDA accepts Summit Therapeutics BLA for lung cancer drug ivonescimab - StreetInsider
Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy - Business Wire
Summit Therapeutics (NASDAQ:SMMT) Sets New 12-Month LowHere's What Happened - MarketBeat
Encouraging Guidance on Clinical Program Makes Summit Therapeutics (SMMT) Look Attractive - Finviz
1.12%
0.87%
자본화:
|
볼륨(24시간):